These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15180818)

  • 1. Annual costs of blood transfusion.
    Watts EJ
    Transfus Med; 2004 Jun; 14(3):247; author reply 249. PubMed ID: 15180818
    [No Abstract]   [Full Text] [Related]  

  • 2. [Platelet substitutes--development and possible clinical applications].
    Murata M
    Rinsho Ketsueki; 1996 Dec; 37(12):1353-61. PubMed ID: 8997122
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood substitutes: science or business?
    Winslow RM
    J Lab Clin Med; 1996 Aug; 128(2):126-7. PubMed ID: 8765207
    [No Abstract]   [Full Text] [Related]  

  • 4. [Health economic aspects of the use of blood and blood products].
    Berger K; Frey L; Spannagl M; Schramm W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):64-72. PubMed ID: 16362134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs of transfusion: economic evaluations in transfusion medicine, Part 1.
    Kacker S; Frick KD; Tobian AA
    Transfusion; 2013 Jul; 53(7):1383-5. PubMed ID: 23560675
    [No Abstract]   [Full Text] [Related]  

  • 6. [Estimating the microcosts of blood transfusion for hemato-oncological patients].
    Brilhante D; Macedo A; Santos A
    Acta Med Port; 2008; 21(6):575-80. PubMed ID: 19331791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes.
    Rao SV; Kaul PR; Liao L; Armstrong PW; Ohman EM; Granger CB; Califf RM; Harrington RA; Eisenstein EL; Mark DB
    Am Heart J; 2008 Feb; 155(2):369-74. PubMed ID: 18215610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.
    Borkent-Raven BA; Janssen MP; van der Poel CL; de Wit GA; Bonsel GJ; van Hout BA
    Transfusion; 2009 Feb; 49(2):311-9. PubMed ID: 19389213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing a framework: economic evaluations in transfusion medicine, part 2.
    Kacker S; Frick KD; Tobian AA
    Transfusion; 2013 Aug; 53(8):1634-6. PubMed ID: 23560640
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis: what it really means for transfusion medicine decision making.
    Custer B; Hoch JS
    Transfus Med Rev; 2009 Jan; 23(1):1-12. PubMed ID: 19056030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs associated with blood transfusions in Sweden--the societal cost of autologous, allogeneic and perioperative RBC transfusion.
    Glenngård AH; Persson U; Söderman C
    Transfus Med; 2005 Aug; 15(4):295-306. PubMed ID: 16101807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternatives to standard blood transfusion: availability and promise.
    Prowse CV
    Transfus Med; 1999 Dec; 9(4):287-99. PubMed ID: 10583882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stop overstocking blood for neurosurgery, study says.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Apr; 13(8):5-7. PubMed ID: 12467268
    [No Abstract]   [Full Text] [Related]  

  • 14. An economic analysis of costs associated with development of a cell salvage program.
    Waters JR; Meier HH; Waters JH
    Anesth Analg; 2007 Apr; 104(4):869-75. PubMed ID: 17377098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of blood components, albumin and artificial colloids. The National Hospital 1979-84].
    Solheim BG; Leivestad T
    Tidsskr Nor Laegeforen; 1986 Aug; 106(23):1842-4, 1840. PubMed ID: 3764862
    [No Abstract]   [Full Text] [Related]  

  • 16. [Health costs analysis of hemophilia in Norway].
    Heger H; Hjort PF; Evensen SA
    Tidsskr Nor Laegeforen; 1980 May; 100(14):948-53. PubMed ID: 7404544
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood program and the possibility of applying red cell substitutes in Indonesia.
    Wikanta M
    Artif Cells Blood Substit Immobil Biotechnol; 1999 Jan; 27(1):43-8. PubMed ID: 10063437
    [No Abstract]   [Full Text] [Related]  

  • 18. Redesigning supply chain management together with the hospitals.
    Rautonen J
    Transfusion; 2007 Aug; 47(2 Suppl):197S-200S; discussion 201S. PubMed ID: 17651350
    [No Abstract]   [Full Text] [Related]  

  • 19. Strengthening the service continuum between transfusion providers and suppliers: enhancing the blood services network.
    Sime SL
    Transfusion; 2005 Oct; 45(4 Suppl):206S-23S. PubMed ID: 16181404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood substitutes: refocusing an elusive goal.
    Winslow RM
    Br J Haematol; 2000 Nov; 111(2):387-96. PubMed ID: 11122077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.